OPC-61815 vs Tolvaptan
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Heart Failure
Shared mechanism: Vasopressin V2 receptor · full Heart Failure pipeline
OPC-61815 · Samtasu
Marketed by Otsuka Holdings
NCT03772041 · Phase 3 · completed
This randomized, double-blind Phase 3 trial compared intravenous OPC-61815 with oral tolvaptan in heart failure with fluid retention, with a non-inferiority primary endpoint on body-weight change. The published analysis reports that non-inferiority was confirmed (difference -0.31 kg, 95% CI -0.68 to 0.06, against a 0.48 kg margin).
Reported efficacy
Change From Baseline in Body Weight (Baseline, Day 6): Change From Baseline in Body Weight (Baseline, Day 6): OPC-61815 Injection 16 mg -1.67 kg (95% CI -1.93 to -1.41) vs Tolvaptan Tablet 15mg -1.36 kg (95% CI -1.62 to -1.1) (met)
Result source: NCT03772041
Tolvaptan · Samsca
Marketed by Otsuka Holdings
NCT00071331 · Phase 3 · completed
This large trial randomly assigned 3,600 people with heart failure to tolvaptan or placebo, with treatment assignment masked. Neither primary outcome favoured tolvaptan: all-cause mortality was 25.9% against 26.3% on placebo (hazard ratio 0.98, 95% CI 0.87 to 1.11, p=0.68), and the combined rate of cardiovascular death or heart-failure hospitalisation was 42.0% against 40.2% (hazard ratio 1.04, 95% CI 0.95 to 1.14, p=0.55). The trial was well built and its answer was that tolvaptan did not change these outcomes.
Reported efficacy
All-cause mortality: tolvaptan 25.9% vs placebo 26.3% (HR 0.98, 95% CI 0.87-1.11, P=.68). Composite of CV death or HF hospitalization: tolvaptan 42.0% vs placebo 40.2% (HR 1.04, 95% CI 0.95-1.14, P=.55). (missed)
Result source: NCT00071331
Results for Heart Failure
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | OPC-61815 | Tolvaptan |
|---|---|---|
| CV death or HF hospitalisation | —Not reported | —Not posted · NCT00071331 |
| HF hospitalisation | —Not reported | —Not posted · NCT00071331 |
| CV death | —Not reported | —Not posted · NCT00071331 |
| KCCQ clinical summary, change | —Not reported | —Not posted · NCT00071331 |
CV death or HF hospitalisation
- OPC-61815
- —Not reported
- Tolvaptan
- —Not posted · NCT00071331
HF hospitalisation
- OPC-61815
- —Not reported
- Tolvaptan
- —Not posted · NCT00071331
CV death
- OPC-61815
- —Not reported
- Tolvaptan
- —Not posted · NCT00071331
KCCQ clinical summary, change
- OPC-61815
- —Not reported
- Tolvaptan
- —Not posted · NCT00071331
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. OPC-61815: 5 of 5 rows · Tolvaptan: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | OPC-61815 | Tolvaptan |
|---|---|---|
| Weight absolute change · kg | -1.67 vs -1.36 Tolvaptan kg @ 0.86wk16 mga,b,c,d NCT03772041 · Phase 3 · monotherapy · Heart Failure · phase 3 | -0.8 vs -1.3 placebo kg @ 1.14wk*a,b,c,d NCT02476409 · Phase 4 · registry result, not featured evidence · converted to kg from -1.8 pounds as posted 3 other source trials-1.62 vs -0.53 placebo kg15 mg NCT00234104 · Phase 2 · registry result, not featured evidence -1.35 vs -0.53 placebo kg30 mg NCT00234104 · Phase 2 · registry result, not featured evidence -1.85 vs -0.53 placebo kg45 mg NCT00234104 · Phase 2 · registry result, not featured evidence |
| Dropout rate | 9.4%16 mge NCT03772041 · Phase 3 · monotherapy · Heart Failure · phase 3 show 8 more results—16 mg NCT03962101 · Phase 3 —8 mg NCT03962101 · Phase 3 —16 mg NCT03510663 · Phase 1 · registry result, not featured evidence —32 mg NCT03510663 · Phase 1 · registry result, not featured evidence 8.3%16mg NCT03254108 · Phase na · registry result, not featured evidence 0%8mg NCT03254108 · Phase na · registry result, not featured evidence 16.7%4mg NCT03254108 · Phase na · registry result, not featured evidence 0%2mg NCT03254108 · Phase na · registry result, not featured evidence | 0%f NCT02476409 · Phase 4 · registry result, not featured evidence show 12 more results0% NCT02183792 · Phase 4 · registry result, not featured evidence 0%Tolvaptan High Copeptin NCT01346072 · Phase 4 · registry result, not featured evidence 0%Tolvaptan Low Copeptin NCT01346072 · Phase 4 · registry result, not featured evidence 16% NCT01439009 · Phase 4 · registry result, not featured evidence 23.3% NCT03255226 · Phase 3 · registry result, not featured evidence 8.5% NCT01644331 · Phase 3 · registry result, not featured evidence 0%30 mg/day NCT00544869 · Phase 3 · registry result, not featured evidence 14.3%15 mg/day NCT00544869 · Phase 3 · registry result, not featured evidence 13.2%15 mg NCT00462670 · Phase 3 · registry result, not featured evidence 14.7%30 mg NCT00234104 · Phase 2 · registry result, not featured evidence 3.4%15 mg NCT00234104 · Phase 2 · registry result, not featured evidence 27.6%45 mg NCT00234104 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 5.4%16 mge NCT03772041 · Phase 3 · monotherapy · Heart Failure · phase 3 show 8 more results—16 mg NCT03962101 · Phase 3 —8 mg NCT03962101 · Phase 3 —16 mg NCT03510663 · Phase 1 · registry result, not featured evidence —32 mg NCT03510663 · Phase 1 · registry result, not featured evidence 8.3%16mg NCT03254108 · Phase na · registry result, not featured evidence 0%8mg NCT03254108 · Phase na · registry result, not featured evidence 16.7%4mg NCT03254108 · Phase na · registry result, not featured evidence 0%2mg NCT03254108 · Phase na · registry result, not featured evidence | —f NCT02476409 · Phase 4 · registry result, not featured evidence show 12 more results— NCT02183792 · Phase 4 · registry result, not featured evidence —Tolvaptan High Copeptin NCT01346072 · Phase 4 · registry result, not featured evidence —Tolvaptan Low Copeptin NCT01346072 · Phase 4 · registry result, not featured evidence — NCT01439009 · Phase 4 · registry result, not featured evidence 3.3% NCT03255226 · Phase 3 · registry result, not featured evidence — NCT01644331 · Phase 3 · registry result, not featured evidence 0%30 mg/day NCT00544869 · Phase 3 · registry result, not featured evidence 7.1%15 mg/day NCT00544869 · Phase 3 · registry result, not featured evidence 9.4%15 mg NCT00462670 · Phase 3 · registry result, not featured evidence 8.8%30 mg NCT00234104 · Phase 2 · registry result, not featured evidence 0%15 mg NCT00234104 · Phase 2 · registry result, not featured evidence 17.2%45 mg NCT00234104 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 4%16 mge NCT03772041 · Phase 3 · monotherapy · Heart Failure · phase 3 show 8 more results0%16 mg NCT03962101 · Phase 3 5.3%8 mg NCT03962101 · Phase 3 0%16 mg NCT03510663 · Phase 1 · registry result, not featured evidence 0%32 mg NCT03510663 · Phase 1 · registry result, not featured evidence 0%16mg NCT03254108 · Phase na · registry result, not featured evidence 0%8mg NCT03254108 · Phase na · registry result, not featured evidence 8.3%4mg NCT03254108 · Phase na · registry result, not featured evidence 0%2mg NCT03254108 · Phase na · registry result, not featured evidence | 31.6%f NCT02476409 · Phase 4 · registry result, not featured evidence show 12 more results0% NCT02183792 · Phase 4 · registry result, not featured evidence 0%Tolvaptan High Copeptin NCT01346072 · Phase 4 · registry result, not featured evidence 0%Tolvaptan Low Copeptin NCT01346072 · Phase 4 · registry result, not featured evidence 48% NCT01439009 · Phase 4 · registry result, not featured evidence 1.7% NCT03255226 · Phase 3 · registry result, not featured evidence 6.2% NCT01644331 · Phase 3 · registry result, not featured evidence 0%30 mg/day NCT00544869 · Phase 3 · registry result, not featured evidence 7.7%15 mg/day NCT00544869 · Phase 3 · registry result, not featured evidence 3.8%15 mg NCT00462670 · Phase 3 · registry result, not featured evidence 3%30 mg NCT00234104 · Phase 2 · registry result, not featured evidence 0%15 mg NCT00234104 · Phase 2 · registry result, not featured evidence 7.1%45 mg NCT00234104 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 16 mge dehydration 10.1% thirst 8.7% constipation 6% NCT03772041 · Phase 3 · monotherapy · Heart Failure · phase 3 show 8 more results16 mg nasopharyngitis 2.1% (placebo 0%) pruritus 2.1% (placebo 0%) tonsillitis 2.1% (placebo 0%) NCT03510663 · Phase 1 · registry result, not featured evidence 32 mg pruritus 8.5% (placebo 0%) nasopharyngitis 2.1% (placebo 0%) tonsillitis 2.1% (placebo 0%) NCT03510663 · Phase 1 · registry result, not featured evidence 16mg back pain 9.1% blood creatinine increased 9.1% blood urea increased 9.1% NCT03254108 · Phase na · registry result, not featured evidence 8mg arthralgia 8.3% blood creatinine increased 8.3% blood urea increased 8.3% NCT03254108 · Phase na · registry result, not featured evidence 4mg vessel puncture site reaction 16.7% abdominal pain upper 8.3% acute kidney injury 8.3% NCT03254108 · Phase na · registry result, not featured evidence 2mg cardiac failure congestive 7.7% contusion 7.7% dizziness 7.7% NCT03254108 · Phase na · registry result, not featured evidence | f thirst 20% (placebo 2%) blood sodium increased 16% (placebo 0%) constipation 12% (placebo 4%) NCT01439009 · Phase 4 · registry result, not featured evidence show 8 more resultsthirst 6.7% anaemia 3.3% constipation 3.3% NCT03255226 · Phase 3 · registry result, not featured evidence worsening heart failure 38% (placebo 46.1%) acute renal failure 18.6% (placebo 11.7%) atrial fibrillation 10.1% (placebo 14.8%) NCT01644331 · Phase 3 · registry result, not featured evidence 30 mg/day blood alkaline phosphatase increased 50% blood creatinine increased 50% blood urea increased 50% NCT00544869 · Phase 3 · registry result, not featured evidence 15 mg/day thirst 46.2% blood creatinine increased 30.8% blood glucose increased 30.8% NCT00544869 · Phase 3 · registry result, not featured evidence 15 mg constipation 17% (placebo 5.3%) thirst 17% (placebo 1.8%) blood urea increased 9.4% (placebo 17.5%) NCT00462670 · Phase 3 · registry result, not featured evidence 30 mg thirst 27.3% (placebo 10.3%) constipation 18.2% (placebo 10.3%) blood uric acid increased 12.1% (placebo 0%) NCT00234104 · Phase 2 · registry result, not featured evidence 15 mg blood uric acid increased 21.4% (placebo 0%) thirst 21.4% (placebo 10.3%) blood urea increased 10.7% (placebo 3.4%) NCT00234104 · Phase 2 · registry result, not featured evidence 45 mg thirst 53.6% (placebo 10.3%) dehydration 21.4% (placebo 6.9%) blood pressure decreased 7.1% (placebo 0%) NCT00234104 · Phase 2 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 4 versus Phase 3.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 1.14 weeks versus 0.86 weeks.
- ePopulation comparability has not been reviewed for 8 of these studies.
- fPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
OPC-61815
Tolvaptan
show 3 more results
show 2 more results
+ 4 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: OPC-61815's landscape · Tolvaptan's landscape